Theriva Biologics Ownership
| TOVX Stock | USD 1.47 0.15 9.26% |
Shares in Circulation | First Issued 1993-03-31 | Previous Quarter 775.7 K | Current Value 1.1 M | Avarage Shares Outstanding 1.8 M | Quarterly Volatility 4.4 M |
Theriva |
Theriva Stock Ownership Analysis
About 21.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.17. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Theriva Biologics recorded a loss per share of 32.59. The entity last dividend was issued on the 13th of August 2018. The firm had 1:25 split on the 26th of August 2024. Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. Theriva Biologics Inc. is headquartered in Rockville, Maryland. Theriva Biologics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 16 people. To find out more about Theriva Biologics contact Steven CPA at 301 417 4364 or learn more at https://therivabio.com.Besides selling stocks to institutional investors, Theriva Biologics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Theriva Biologics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Theriva Biologics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Theriva Biologics Quarterly Liabilities And Stockholders Equity |
|
About 10.0% of Theriva Biologics are currently held by insiders. Unlike Theriva Biologics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Theriva Biologics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Theriva Biologics' insider trades
Theriva Biologics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Theriva Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Theriva Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Theriva Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kraws Jeffrey J over a year ago Acquisition by Kraws Jeffrey J of 110000 shares of Theriva Biologics subject to Rule 16b-3 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.